Guangdong Association Of Clinical Trials

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer DNA (ctDNA) remains detectable in the blood after a few weeks on the drug osimertinib alone. Those patients tend to do worse, so researchers want to see if adding a second drug (sacituzuma…

This study is for people with stage II-IIIB non-small cell lung cancer who had surgery after initial chemotherapy and immunotherapy but still had some cancer cells left. Researchers want to see if using a sensitive blood test (MRD) to guide additional treatment with the immunothe…

This study tests a combination of two drugs, IBI351 and cetuximab β, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if this treatment can shrink tumors or slow the cancer's growth. About 48 adults who hav…

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 will take part. The goal is to see if this combo can …